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Background: Cancer stem cell model hypothesizes existence of a small proportion of tumor cells capable of
sustaining tumor formation, self-renewal and differentiation. In breast cancer, these cells were found to be
associated with CD44+CD24-low and ALDH+ phenotype. Our study was performed to evaluate the suitability of
current approaches for breast cancer stem cell analyses to evaluate heterogeneity of breast cancer cells through
their extensive genetic and epigenetic characterization.
Methods: Breast cancer cell lines MCF7 and SUM159 were cultured in adherent conditions and as mammospheres.
Flow cytometry sorting for CD44, CD24 and ALDH was performed. Sorted and unsorted populations,
mammospheres and adherent cell cultures were subjected to DNA profiling by array CGH and methylation profiling
by Epitect Methyl qPCR array. Methylation status of selected genes was further evaluated by pyrosequencing.
Functional impact of methylation was evaluated by mRNA analysis for selected genes.
Results: Array CGH did not reveal any genomic differences. In contrast, putative breast cancer stem cells showed
altered methylation levels of several genes compared to parental tumor cells.
Conclusions: Our results underpin the hypothesis that epigenetic mechanisms seem to play a major role in the
regulation of CSCs. However, it is also clear that more efficient methods for CSC enrichment are needed. This work
underscores requirement of additional approaches to reveal heterogeneity within breast cancer.Background
Breast cancer is the most commonly diagnosed cancer
and the leading cause of cancer death in women [1].
Despite combined treatment strategies and advances in
treatment, metastatic breast cancer remains currently in-
curable. One of the possible reasons for therapeutic fail-
ure is the existence of tumor cell heterogeneity and
presence of cancer stem cells (CSCs) [2]. There are sev-
eral indicators of intratumoral heterogeneity, including
recognized prognostic and predictive markers and candi-
date biomarkers [3,4]. Among the clinically established
biomarkers are estrogen and progesterone receptor, and
human epidermal growth factor receptor 2 (Her2-neu)
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reproduction in any medium, provided the orpresence of breast CSCs [6,7]. Increasing experimental
evidence supports the cancer stem cell model [8], which
is in favor of only a small proportion of cells with the
capability of sustaining tumor formation and growth,
self-renewal and differentiation. In breast cancer, CSCs
have been identified as CD44+CD24-/low or aldehyde de-
hydrogenase positive (ALDH+) [9,10]. Several approaches
have been used to enrich and study breast CSCs, including
flow cytometry sorting and their capability of forming
mammospheres [9,11]. Tumor sphere culture has been
shown to represent a surrogate in vitro model to study
CSCs [12,13]. Identification of distinct properties and mo-
lecular biomarkers for breast CSCs may help to identify
novel therapeutic targets and thereby allow development
of more efficient therapeutic strategies [14].
We aimed to evaluate molecular heterogeneity of breast
cancer cell lines with an emphasis on breast CSCs. For
unsorted breast cancer cells and flow-sorted putative stem
versus non-stem cells, DNA profiles were generated by
array comparative genomic hybridization (aCGH) andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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by pyrosequencing. Functional impact of methylation was
evaluated by mRNA analysis for selected genes.
Methods
Breast cancer cell lines
Breast cancer cell lines MCF7 and SUM159 were used for
all experiments. SUM159 were obtained from Asterand
(Detroit, MI, USA), and MCF7 from American Type Cul-
ture Collection (Manassas, VA, USA). Cells were cultured
according to suppliers’ recommendations, harvested at
90% confluence and prepared for further analyses.
Mammosphere culture
The culture of mammospheres (MMO) was performed
according to previous publications [11]. Briefly, cells were
grown in serum-free Mammary Epithelial Basal medium
MEBM (Lonza, Basel, Switzerland), supplemented with
10 ng/mL basic fibroblast growth factor (bFGF), 20 ng/mL
epidermal growth factor (EGF), 5 μg/mL insulin (both from
Peprotech, New York, USA), and 20 μl/ml B27 supplement
(Invitrogen, Leek, Netherlands). After the first passage,
the mammospheres were filtered through a 40-μm Nylon
Cell Strainer (BD, Falcon) to obtain purer spheres for fur-
ther culture. The cells were then dissociated with TrypLE
(Gibco/Invitrogen, Paisley, Renfrewshire, UK), following in-
cubation at 37°C for 4 min. The cells were washed with
two volumes of PBS (phosphate buffer saline) to inactivate
the enzyme, resuspended in MEBM containing supple-
ments and seeded for generation of secondary spheres.
Flow cytometry
For all sorting experiments cells were dissociated with
Accutase (PAA Laboratories GmbH, Pasching, Austria)
for 5 min at 37°C. When using the Aldefluor protocol [10],
dissociated cells were suspended in Aldefluor assay buffer
to a concentration of 106 cells/ml. When performing anti-
CD44 and anti-CD24 flow-sorting [9], 106 cells were
suspended in 100 μl of PBS/2% fetal calf serum (FCS).
After 20 min of incubation on ice with blocking buffer
consisting of horse serum diluted 1:20 in 6% bovine serum
albumin/PBS solution, aliquots of antibodies (CD44 APC
and CD24 FITC), each at a dilution of 1:40 in a final con-
centration of 0.08 μg/ml and 5 μg/ml, respectively, were
added and staining was adapted from the previously pub-
lished protocol [9]. Briefly, after centrifugation the pellet
was dissolved in 100 μl PBS/FCS and 2.5 μl of the anti-
bodies (CD24-FITC and CD44-APC) were mixed with the
cells and incubated for 20 min on ice. Then, cells were
washed with 500 μl PBS/FCS and centrifuged again. Before
sorting, cells were resuspended in 100 μl PBS/FCS, filtered
and rinsed with 100 μl PBS/FCS. All fluorochrome-labeled
monoclonal antibodies were acquired from BD Bioscience
and pretitered to determine their optimal dilutions beforeuse. Cells without staining and isotype controls, also
from BD Bioscience, were integrated as controls in all
experiments.
Aldefluor assay
Cells with high ALDH activity in MCF7 and SUM159 cells
were isolated using the Aldefluor Kit (StemCell Technolo-
gies, Durham, NC, USA) according to the manufacturer’s
instructions and as previously published [10,15]. Cells iso-
lated with Aldefluor Kit were used for genetic and epigen-
etic analysis. Flow cytometry sorting was performed on
the Aria fluorescence activating cell sorter (FACS) and ac-
quired data were analyzed using the Diva software (BD
Bioscience).
DNA extraction
Genomic DNA from cultured cells was extracted using the
Gentra Puregene Blood Kit (Qiagen) according to the
manufacturer's protocol. DNA was dissolved in a final vol-
ume of 100 μL buffer and quantified spectrophotometrically
using a BioPhotometer (Eppendorf, Hamburg, Germany).
Evaluation of genomic profiles
Whole genome amplification (WGA)
DNA from sorted SUM159 subpopulations (ALDH+,
ALDH-, CD44+CD24-, CD44+ CD24+) and manually picked
SUM159 and MCF7 mammospheres were amplified using
the GenomePlex Single Cell Whole Genome Amplification
Kit (Sigma-Aldrich, St. Louis, MO, USA) following the in-
structions of the manufacturer. To prevent any loss, cells
were sorted directly into tubes where cell lysis and WGA
were performed. Briefly, the volume was adjusted with
water to 9 μl. After cell lysis and Proteinase K digest the
DNA was fragmented and libraries were prepared. These
products were used as templates for the amplification reac-
tion which was performed in a thermal cycler (95°C for
3 min, 25 cycles of 94°C for 30 seconds and 65°C for 5 min,
hold 4°C) by adding 7.5 μL of 10 ×Amplification Master
Mix, 48.5 μL of nuclease-free water and 5 μL WGA DNA
polymerase. Amplified samples were purified using Gen-
Elute PCR Clean-up Kit (Sigma-Aldrich, St. Louis, MO,
USA) and quantified by measuring absorbance on a Nano-
Drop Spectrophotometer (Thermo Scientific, MA; USA).
The quality of the amplification was evaluated using a
multiplex PCR [16].
Samples with significantly lower than the expected
average DNA concentration of 250 ng/μl after WGA, or
samples that showed only one band in multiplex PCR
were excluded from further analyses.
Array CGH (aCGH)
Array CGH was carried out using a genome-wide oligo-
nucleotide microarray platform (Human genome CGH
60 K microarray kit, Agilent Technologies, Santa Clara,
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and employing commercially available male reference
DNA (Promega, Madison, WI, USA). Briefly, 500 ng DNA
from SUM159 and MCF7 was digested with restriction
endonucleases AluI/RsaI at 37°C for two hours, followed
by an enzyme inactivating step at 65°C for 20 min. A
smear between 2000 and 100 bp on a 1% agarose gel indi-
cated successful digestion. Due to the previous fragmenta-
tion during the WGA this step was omitted for amplified
samples (e.g. DNA of cultured MMO of both cell lines
and sorted SUM159).Figure 1 Expression of putative stem cell markers in breast cancer ce
CD24 expression in SUM159 (left) and MCF7 (right) breast cancer cell line. T
cells defined as CD44+CD24-/low. (B) Aldefluor analysis measuring ALDH exp
percentages reflect the Aldefluor positive population of the cells.Samples were then labeled with the Bioprime array
CGH genomic labeling system (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. Five
hundred ng each of the test DNA and the reference DNA
were differentially labeled with dCTP-Cy5 or dCTP-Cy3
(GE Healthcare, Milwaukee, WI, USA). Unincorporated
nucleotides were removed using the Amicon KD30
Kit (Millipore, Billerica, MA, USA). The probes were
quantified before hybridization by determining the ab-
sorbance at 260 nm (DNA), 550 nm (cyanine 3), and 650
nm (cyanine 5) using NanoDrop spectrophotometer andll lines MCF7 and SUM159. (A) FACS analysis measuring CD44 and
he percentages reflect the population of putative breast cancer stem
ression in SUM159 (left) and MCF7 (right) breast cancer cell line. The
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cooling to room temperature. After annealing for 30 min
at 37°C, array hybridization was carried out at 65°C for 24
hours with about 200 ng probes/array in Agilent HI-RPM
hybridization buffer. Slides were scanned using a micro-
array scanner (#G2505B; Agilent Technologies, Santa
Clara, CA, USA), and images processed using Feature Ex-
traction and DNA Workbench 5.0.14 (Agilent Technolo-
gies). In addition, data normalization and calculation of
ratio values was performed using the Feature Extraction
software 9.1 from Agilent Technologies. Evaluation of data
was done based on the previously published algorithm
in R (www.r-project.org) [17]. The algorithm calculates
ratio values with different window sizes that differ sig-
nificantly from the mean of the ratio profile and are there-
fore considered as over- or under-represented graphically
indicated in a single green or red bar for gained or lost re-
gions, respectively. Furthermore, the algorithm generates
a table with all localizations of significant calls, which
allows detailed mapping of each copy number variation
(CNV).
Evaluation of epigenetic profiles
Epitect methyl qPCR arrays
To identify relevant gene promoter methylation we used
EpiTect Methyl qPCR Arrays (SA Biosciences, Qiagen,
Hilden, Germany) as a screening method. We analyzed 96
cancer-related genes from four pathways including stemFigure 2 Representative images from parental MCF7 and SUM159 cel
spheres within half of the time as compared to MCF7.cell transcription factors, homeobox genes, wnt signal-
ing, and epithelial to mesenchymal transition (EMT).
Assays were performed according to the manufacturer’s
instructions. Results were displayed as percentage of
unmethylated and methylated fraction.
Pyrosequencing
For methylation analysis by pyrosequencing, one μg of
genomic DNA was subjected to bisulfite conversion with
the EpiTect Bisulfite Kit (Qiagen) according to the man-
ufacturer's instructions. The purified bisulfite converted
samples were eluted in 40 μl volume and stored at −20°C
for further analysis.
To quantify the percentage of methylated cytosine in
individual CpG sites, bisulfite-converted DNA was ana-
lyzed using pyrosequencing (Pyromark® Q24, Qiagen) as
previously described [18]. Custom Pyromark® CpG as-
says were used for following genes: HOXB4, HDAC1,
FOXA2, CTBP1, LEF1, SMAD2, DSC2 and HIF1A. For
genes HOXD3 and WIF1 assays were designed using the
Pyromark Assay Design Software Version 2. Following






GGGGTTTTTTAGGGGG-3′.ls and corresponding MMO. SUM159 formed significantly larger
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Total RNA was extracted from parental adherent cells,
MMO or sorted cells using TRIzol Reagent (Invitrogen,Figure 3 Array CGH profiles of MCF7 parental cell line, a pool of 6 MM
MCF7 between genomic DNA of the parental cell line and the correspond
regions, lost regions appear in red and gained regions in green.Carlsbad, CA, USA) according to the manufacture’s rec-
ommendation. RNA was quantified and assessed for pur-
ity by UV spectrophotometry. One microgram of totalO and a single MMO. No significant copy number differences of
ing MMO were observed. Black parts in the profile represent balanced
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verse Transcription Kit (Qiagen) according to the manu-
facturer’s instructions.
qPCR was performed using LightCycler 480 (Roche).
Reactions were performed in a total volume of 20 μl,Figure 4 Array CGH profiles of SUM159 parental cell line, a pool of 3
SUM159 between genomic DNA of the parental cell line and the correspon
balanced regions, lost regions appear in red and gained regions in green.comprising 1x SYBR Green I Master Mix (Roche), 20 ng
cDNA and 25 μM of each primer (final concentration).
All qPCR reactions were performed in duplicate and
quantification cycle values were averaged. Gene expres-
sion was calculated by the comparative Ct method [19]MMO and a single MMO. No significant copy number differences of
ding MMO were observed. Black parts in the profile represent
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differences over that in the parental monolayer cells.
Hydroxymethylbilane synthase (HMBS) expression was
used as internal control.
Following RT-qPCR primers were chosen from the
public database (http://www.rtprimerdb.org) [20,21], gene
(RTPrimerDB-ID): HOXD3 (4603), HIF1A (7974), RGS2
(7770), CTBP1 (4471), LEF1 (8496), HDAC1 (442) and
HMBS (4). The program Primer3 (NCBI, Primer-BLAST,
http://www.ncbi.nlm.nih.gov/tools/primer-blast) was used




Quantitative data are represented as the mean ± SD. For
comparison of means, we used Student’s t-test andFigure 5 Array CGH profiles after separation of SUM159 ALHD+ and A
SUM159 between ALDH+ and ALDH- subpopulation were observed. Black p
red and gained regions in green.ANOVA with Tukey multiple comparison as a post hoc
analysis. Statistical significance was defined as p < 0.05.
GraphPad Prism software version 6 (GraphPad Software,
La Jolla, California, USA) was used for statistical analysis.
Results
Putative stem cell phenotypes in breast cancer cell lines
Flow cytometry was used to assess the expression of puta-
tive stem cell markers in MCF7 and SUM159 cells, includ-
ing CD44, CD24, and ALDH. As shown in Figure 1A,
MCF7 cells had a low amount of CD44+CD24-/low cells
(1.1%), whereas SUM159 cells showed a high proportion
of CD44+CD24-/low cells (96.1%). In addition, the ALDH
activity was evaluated. Figure 1B illustrates that MCF7
cells showed low ALDH positivity (0.6%), in contrast to
SUM159 cells where we detected an increased ALDH ac-
tivity (8.4%).LDH- subpopulation. No significant copy number differences of
arts in the profile represent balanced regions, lost regions appear in
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enriched stem cell phenotype.Mammosphere formation assay
MCF7 and SUM159 were both able to generate MMO
in non-adherent conditions. For generation of MMO in
first passage, MCF7 remained in non-adherent conditions
for 10 days. After filtration and dissociation of spheres, an-
other 10 days were needed for generation of secondary
spheres. SUM159 cells were able to form spheres after 5
days. Analogous to the MCF7 MMO culture, secondary
spheres were generated, which required 5 days. Parental
cultures and corresponding representative spheres are
depicted in Figure 2. As indicated in the figure and previ-
ously suggested [22], SUM159 were capable of forming
significantly larger spheres within half of the time. SingleFigure 6 Array CGH profiles after separation of SUM159 between CD4
number differences of SUM159 between CD44+CD24- and CD44-CD24+ sub
balanced regions, lost regions appear in red and gained regions in green.spheres and pools of spheres were manually picked and
subjected to further profiling analyses.
Genomic profiles of putative breast CSCs
We employed aCGH to analyze 10 manually picked
spheres each from MMO cultures of SUM159 and MCF7
and compared them with cells grown in adherent culture.
From both SUM159 and MCF7 two spheres were
excluded from further analyses due to either low DNA
concentrations following WGA or incomplete target
amplification in the multiplex PCR. All other spheres
showed 4 bands after PCR, with an average yield of
10 μg and 12 μg for SUM159 and MCF7, respectively.
We observed no significant copy number differences for
MCF7 between genomic DNA of the parental cell line
and the corresponding MMO. All samples showed the
same genomic aberrations including high-level gains at4+CD24- and CD44-CD24+ subpopulation. No significant copy
population were observed. Black parts in the profile represent
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13q, 18q and 22q. Most regions of chromosome 4 were
underrepresented (Figure 3). These changes are in line
with previously published copy number profiles for MCF7
[23,24]. For SUM159 we obtained similar results. We ob-
served high-level amplifications of 3q and 5p, losses atFigure 7 Heat maps of CGH-profiles from SUM159 parental cell line c
male reference DNA in all experiments and therefore female plasma DNA s
an under- representation of the Y-chromosome (black: balanced; red: unde17p and 21q, and a complete loss of chromosomes 4, 19
and 22 in all samples (Figure 4).
Since MMO displayed no significant copy number
variation compared to the parental cell lines, we further
wanted to determine whether different cell subpopula-
tions of SUM159 exhibit distinct differences in theirompared to sorted subpopulations and to single MMO. We used
amples have a relative over-representation of the X chromosome and
r-represented; green: over-represented).
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populations (ALDH+, ALDH-, CD44+CD24-, CD44+CD24+)
were subjected to WGA followed by aCGH. Again, we
did not detect any difference in the copy number profile
even after separation of cell populations (ALDH+ and
ALDH– cells are shown in Figure 5 and CD44+CD24- cells
vs. CD44 –CD24+ in Figure 6).
This data is summarized in heat maps of aCGH profiles
for SUM159 (Figure 7) and MCF7 (Figure 8), respectively.
Minor differences in CNV that mainly include single, non-Figure 8 Heat maps of CGH-profiles from MCF7parental cell
line compared to single MMO. We used male reference DNA in all
experiments and therefore female plasma DNA samples have a
relative over-representation of the X chromosome and an
under- representation of the Y-chromosome (black: balanced; red:
under-represented; green: over-represented).adjacent oligonucleotides most likely represent artifacts in-
troduced during the amplification process. Nevertheless,
amplification artifacts with the single cell amplification,
which may result in under- (e.g. allele drop out) or over-
representations (e.g. preferential amplifications) are prob-
ably rare as we previously reported [17].
Methylation analysis of putative breast CSCs
Based on the assumption that heterogeneity of the cells
may be driven by epigenetic changes, we screened pro-
moter methylation of 96 candidate genes in parental
breast cancer cells and putative breast CSC using Epitect
Methyl qPCR Arrays (results are summarized in Figure 9).
We selected a panel of candidate genes showing differential
methylation for further methylation analysis using bisulfite
pyrosequencing. These genes included HOXD3, WIF1,
HIF1A, RGS2, DSC2, SMAD2, FOXA2, CTBP1 and LEF1
for MCF7 and WIF1, HDAC1, HOXD3 and HOXB4 for
SUM159. Two biological replicates of each condition were
included in the pyrosequencing analysis. Again, parental
cells and MMO were analyzed. In addition, the sorted sub-
populations (ALDH+, ALDH-, CD44+CD24-, CD44+CD24+)
from SUM159 cells were also analyzed. Sorted MCF7 cells
could not be analyzed since the percentage of cells with pu-
tative breast cancer stem cell phenotype was too low.
In MCF7, four of 9 genes showed significantly differ-
ent methylation levels between parental and MMO cells.
These genes included WIF1, DSC2, FOXA2 and LEF1
(Figure 10A). Compared to MMO, WIF1 and LEF1 showed
lower methylation levels, while DSC2 and FOXA2 showed
higher methylation levels. To test whether methylation of
candidate gene promoters affects the expression of corre-
sponding genes, we analyzed mRNA expression levels in
parental and MMO cells. WIF1, HIF1A, RGS2 and LEF1
showed a significantly higher expression in MMO com-
pared to parental MCF7 cells (Figure 10B). WIF1 and LEF1
showed an inverse relationship between methylation level
and mRNA expression. HOXD3 and CTBP1 mRNA levels
were similar in MMO and parental MCF7 cells. This is in
line with the methylation results, which were also similar in
both conditions.
Generally, Epitect Methyl qPCR Arrays revealed less
detectable methylation differences in SUM159 cell line.
Applying bisulfite pyrosequencing, four selected candidate
genes showed higher methylation levels between MMO
and parental cells, with HOXD3 being the only gene with
significantly higher levels (Figure 10C). Regarding gene ex-
pression, WIF1, HDAC1 and HOXD3 mRNA levels were
significantly higher in SUM159 MMO cells than in paren-
tal cells (Figure 10D). Hence, there was no inverse correl-
ation between HOXD3 methylation and gene expression.
To test whether culturing tumor cells in non-adherent
condition could affect methylation of the genes analyzed,
we also subjected sorted subpopulations of SUM159 cells
Figure 9 Differential promoter methylation profile of candidate genes in parental breast cancer cells (MCF7 P and SUM159 P) and
putative breast CSC (MMO). Methylation status of 96 genes was analyzed using the Epitect Methyl qPCR Arrays (Qiagen). Methylation level is
expressed in a 0-100% scale, with higher methylation shown in red and lower methylation shown in green. For MCF7, we identified a set of 19
genes differentially methylated in mammospheres compared to parental cells. 13 of these genes were hypermethylated and six genes were
hypomethylated in mammospheres. For SUM159, we found only four differentially methylated genes and all these genes were hypomethylated
in mammospheres.
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methylation analysis. WIF1 and HDAC1 showed similar
levels of gene methylations in all sorted subpopulations and
MMO cells, but lower levels for parental SUM159 cells. In
contrast, HOXD3 was similarly methylated at lower levels
in all sorted populations, but higher methylation levels were
found in MMO and parental cells. HOXB4, on the other
hand, was similarly higher methylated in sorted popula-
tions, but less methylated in MMO and parental cells.
These results are summarized in Figure 10E. mRNA ex-
pression levels of WIF1, HDAC1 and HOXD3 were differ-
ent in distinct sorted populations compared to MMO and
parental SUM159 cells (Figure 10F).
Discussion
This is the first study to analyze both genetic and epi-
genetic alterations in putative breast cancer stem cell
models derived from established breast cancer cell lines.
At the genomic level we did not find any copy number
variations between putative breast cancer stem cells (i.e.
mammospheres or sorted subpopulations) and the corre-
sponding parental tumor cells. In contrast, putative breast
cancer stem cells showed altered methylation levels of sev-
eral genes compared to parental tumor cells.Definition and analysis of CSCs remains a challenge.
Among the approaches to enrich and study the cancer
stem cell biology are in vitro cultures and flow cytometry
sorting based on defined putative phenotypes of CSCs
for different diseases [9,10,25,26]. We focused our analyses
on evaluation of genetic and epigenetic profiles in an at-
tempt to associate the heterogeneity with the presence of
putative CSCs within breast cancer cell lines. Parental cell
lines and MMO originating from the parental cell line and
distinct populations defined by putative breast cancer
stem cell phenotypes were compared.
Two biologically distinct breast cancer cell lines were
used: MCF7 represents luminal breast epithelial tumor
cells, and SUM159 represents triple negative breast epi-
thelial tumor cells. The phenotypes we used to enrich
for breast CSCs were established earlier by Al Hajj et al.
[9] and Ginestier et al. [10], and are commonly used to
address breast CSCs. Ability of these two cell lines to
form MMO was previously demonstrated by us and others
[15,22,27]. The proportions of putative breast CSC sub-
populations we observed in both cell lines were compar-
able with published results [22,28,29].
This is the first comparison of aCGH profiles between
parental cells and MMO for both cell lines, and indicates
Figure 10 Association between DNA promoter methylation and mRNA expression of selected candidate genes in parental MCF7 and
SUM159 cells and their corresponding CSC phenotype. DNA methylation was assessed by pyrosequencing and mRNA expression by qRT-PCR.
Bars represent average and SD of two biological replicates. *p < 0.05. (A) DNA promoter methylation and (B) mRNA expression levels in parental
and MMO MCF7 cells. (C) DNA promoter methylation and (D) mRNA expression levels in parental and MMO SUM159 cells. (E) DNA promoter
methylation and (F) mRNA expression levels in sorted subpopulations of SUM159 cells.
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the analyzed samples. One explanation for the similar
genotype could be the fact that CSCs give rise to all pro-
genitor cells and therefore both share the same genetic
profile. However, studies suggest that cancers may containmultiple CSC clones, arising through clonal evolution in
CSCs [8]. Such CSC clones are more likely to be found
in primary tumors rather than in cell lines. In addition, al-
though CSCs are enriched in these models, not all cells
within the mammosphere population represent cells with
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the CSC signature, both genetically and epigenetically, is
unknown.
Genomic profile of MCF7 cells was comparable with
results published for adherent cell cultures [23,24]. We
did not find matching data for SUM159. As expected,
owing to their very distinct biology, MCF7 and SUM159
had substantially different genomic profiles.
Proposed plasticity and dynamic property of cancer
cells, often associated with the ability to undergo EMT
and reverse and to switch stem cell markers off and back
on, suggest an underlying epigenetic mechanism [30-32].
These properties determine metastatic potential of tu-
mors [33], and may be the reason why most dissemi-
nated tumor cells in bone marrow have the putative
breast CSC phenotype, as we have shown previously [34].
Epigenetic regulation of common CSC genes has recently
been demonstrated in triple negative breast cancer [35].
Furthermore, in a recent paper, Park et al. have demon-
strated distinct methylation pattern across defined intrin-
sic molecular breast cancer subtypes and their correlation
with described breast CSC markers in archival primary
breast cancer tissues [36]. In concordance to our findings
in breast cancer cell lines, primary cancer tissues of triple
negative breast cancer had higher frequency of ALDH+
and CD44+CD24- cells. Therefore, our further analyses fo-
cused on analyzing methylation profiles of putative breast
CSCs in vitro. Genes screened by methylation arrays were
chosen according to the potentially important molecular
pathways involved in stem cell biology, including stem cell
transcription factors, homeobox genes, wnt signaling and
EMT. Selected differentially methylated genes were fur-
ther evaluated by bisulfite pyrosequencing.
Bisulfite pyrosequencing revealed differences in methy-
lation levels between parental and MMO cells and also be-
tween sorted populations and MMO cells. Differences in
sorted subpopulations may reflect not only the heterogen-
eity in CSCs, but also different ability to enrich for CSC.
As already stated, enrichment factor for CSCs is unknown
for both approaches. In case of the SUM159 cell line, the
majority of cells were associated with CD44+CD24- CSC
phenotype. These cells are more aggressive, basal like, with
mesenchymal characteristics, and with most of the cells be-
ing similar, detection of differentially expressed markers is
less likely.
Several groups have used a similar approach in attempt
to associate intratumoral heterogeneity with the presence
of CSCs. Clearly, the main goal of such an approach is to
understand the biological mechanism and finally identify
biomarkers of CSCs to design better treatment strategies.
One of the first studies was published by Hernandez-
Vargas et al. [37], revealing JAK-STAT pathway activation
in putative breast CSCs defined as CD44+CD24- MCF7
cells. Hypomethylation of genes in JAK- STAT pathwaywas demonstrated further in MMO. The authors provided
not only a potential definition of biomarkers associated
with CSCs, but also an evidence of underlying epigenetic
regulation of CSC properties. In a similar analysis in hepa-
tocellular carcinoma, researchers identified epigenetic reg-
ulation of wnt signaling as a potential biomarker of early
detection and therapeutic targeting [38]. Epigenetic mech-
anisms and the role of miRNA regulation of CSCs have
also been demonstrated [39,40] providing a new insight
into biology and potential definition of novel therapeutic
targets. All these analyses are promising and require fur-
ther evaluation.
Finally, our mRNA analyses suggest that although some
genes showed an inverse correlation between methylation
and gene expression, other mechanisms than DNA pro-
moter methylation may be responsible for regulating gene
expression. In our study, methylation seemed to play a
role only in the regulation of WIF1 and LEF1 in MCF7.
One reason for the lacking correlation might be heteroge-
neous promoter methylation and that at least in part our
methylation assay did not detect the regulating region.
Also, further mechanisms might be involved in epigenetic
silencing of proteins, including histone modifications, long
noncoding RNAs and miRNAs [41]. These mechanisms
are incompletely understood and are emerging study
topics. However, their evaluation was out of the scope of
the present study.
Our results, along with others, clearly underpin the hy-
pothesis that epigenetic mechanisms play a major role in
the regulation of CSCs, however, more efficient methods
for CSC enrichment are needed. Other mechanisms of
epigenetic regulation have also to be taken into account.
Moreover, these analyses should be extended to patient
samples, in order to validate results, and possibly find
higher heterogeneity than possible and present in cell lines.
Conclusions
In conclusion, stem cell hypothesis has to be further
challenged; we need additional markers and more effi-
cient approaches and models in order to better define
the biology of stem cells and identify biomarkers for
early diagnosis and treatment with higher precision.
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